GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million
Tuesday, October 6, 2026 · first reported by HedgeCo Insights
Trilantic North America agrees to sell SOFIE Biosciences (PET radiopharmaceutical contract manufacturer) to GE HealthCare for $945M; SOFIE operates 15 U.S. manufacturing sites with 21 cyclotrons and U.S. rights to FAPI-74 experimental imaging agent.
- Also named
- GE HealthCare, SOFIE Biosciences
- Deal value
- $945M
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Mubadala Capital completes $6.2bn take-private of Clear Channel OutdoorPE Hub
- EQT to acquire US real estate manager StockbridgePE Hub +2
- Blackstone inks $1.5bn sale of ZO Skin Health to GaldermaPE Hub +1
- LSEG Is in Discussions With Permira to Acquire Octus for About $3.5 BillionHedgeCo Insights
- GHK closes acquisition of Southeast home services platform USA Hometown ExpertsPE Hub
- Align Collaborate and Valedor-backed Q360 Group acquires The Flexo FactorPE Hub